- Home
- RPRX
RPRX
Royalty Pharma plc
as 10-16-2025 3:56pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 15.6B | IPO Year: | 2020 |
| Target Price: | $44.50 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.32 | EPS Growth: | 54.86 |
| 52 Week Low/High: | $24.05 - $38.00 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,305,243,000 | Revenue Growth: | 3.02% |
| Revenue Growth (this year): | 35.14% | Revenue Growth (next year): | 1.24% |
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Norden Gregory | RPRX | N/A | Aug 11 '25 | Sell | $36.23 | 33,500 | $1,213,748.55 | 194,848 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally?
StockStory
4 days ago
3 Healthcare Stocks We Keep Off Our Radar
GlobeNewswire
7 days ago
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
Insider Monkey
15 days ago
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
GlobeNewswire
a month ago
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Insider Monkey
a month ago
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
StockStory
a month ago
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
Insider Monkey
a month ago
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.